[Federal Register Volume 78, Number 106 (Monday, June 3, 2013)]
[Notices]
[Page 33097]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-13043]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[CDC-2013-0007; NIOSH-233]
NIOSH List of Antineoplastic and Other Hazardous Drugs in
Healthcare Settings 2014: Proposed Additions and Deletions to the NIOSH
Hazardous Drug List
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of Draft Document Available for Public Comment.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC)
announces the availability of the following draft document for public
comment entitled ``NIOSH List of Antineoplastic and Other Hazardous
Drugs in Healthcare Settings 2014: Proposed Additions and Deletions to
the NIOSH Hazardous Drug List.'' The document and instructions for
submitting comments can be found at http://www.regulations.gov.
This guidance document does not have the force and effect of law.
Public Comment Period: Comments must be received by August 2, 2013.
ADDRESSES: You may submit comments, identified by CDC-2013-0007 and
Docket Number NIOSH-233, by either of the two following methods:
Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: NIOSH Docket Office, Robert A. Taft Laboratories,
MS-C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226.
Instructions: All information received in response to this notice
must include the agency name and the docket number (CDC-2003-0007;
NIOSH-233). All relevant comments received will be posted without
change to http://www.regulations.gov, including any personal
information provided. All electronic comments should be formatted as
Microsoft Word. Please make reference to CDC-2013-0007 and Docket
Number NIOSH-233.
SUPPLEMENTARY INFORMATION:
Background: The NIOSH Alert: Preventing Occupational Exposures to
Antineoplastic and Other Hazardous Drugs in Health Care Settings was
published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/).
This Alert contained Appendix A which was a list of drugs that were
deemed to be hazardous and may require special handling. This list of
hazardous drugs was updated in 2010 and 2012 and covered all new
approved drugs and drugs with new warning up to December 2009. (http://www.cdc.gov/niosh/docs/2010-167/; http://www.cdc.gov/niosh/docs/2012-150/). Between January 2010 and December 2011, 48 new drugs received
FDA approval and 276 drugs received special warnings (usually black box
warnings) based on reported adverse effects in patients. From this list
of 324 drugs, 42 drugs were identified by NIOSH as candidate hazardous
drugs. Four of these drugs had safe handling recommendations from the
manufacturer and NIOSH is following the recommendations of the
manufacturers. Therefore, these four drugs will be listed as hazardous
without requiring further review. A panel consisting of peer reviewers
and stakeholders was asked to review and comment on the remaining 38
potentially hazardous drugs. In addition, the panel members were asked
to comment on the addition of one drug requested by several
stakeholders and the removal of one drug from the 2012 Hazardous Drug
List. Reviewers were not asked to provide a consensus opinion and NIOSH
made the final determination regarding additions and deletions to the
2014 hazardous drug list.
NIOSH reviewed the recommendations of the peer reviewers and
stakeholders and determined that 24 drugs in addition to the 4 drugs
with manufacturer's warnings, were determined to have one or more
characteristics of a hazardous drug and this list of 28 drugs is being
published for comment in CDC-2013-0007 and NIOSH Docket Number 233. In
addition, 1 drug from the 2012 Hazardous Drug List is being considered
for removal. The complete list of these drugs can be found at: http://www.regulations.gov as a supporting document.
FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A.
Taft Laboratories, 4676 Columbia Parkway, MS-C26, Cincinnati, Ohio
45226, telephone (513) 533-8132, Email [email protected].
Dated: May 24, 2013.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2013-13043 Filed 5-31-13; 8:45 am]
BILLING CODE 4163-19-P